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ABSTRACT 
 
Intellectual property protection in the form of secured patents has played an 
integral role in the growth and advancement of the biotechnology industry. The 
protection of intellectual properties is considered very important asset in this evolving 
industry. As a result, patent disputes often end up in the courts with long lasting 
consequences.  Here we examined two recent and highly publicized patent dispute cases, 
namely, Mayo Collaborative Services et al. v. Prometheus Laboratories, Inc. (2012) and 
Association for Molecular Pathology et al. v. Myriad Genetics (2011), and wish to assess 
how the rulings will impact diagnostics and personalized medicine industries. In doing 
so, we learned that decisions involving patents are complex and interconnected, with 
previous court rulings influencing subsequent cases. It also became clear that in general, 
the biotechnology industry favored patent protection while healthcare providers and their 
patients favored less stringent patent protection. The case is made by the biotechnology 
industry that the current system has allowed both the diagnostics and personalized 
medicine industries to flourish. Patents are a crucial incentive that not only promotes but 
 v 
also protects innovation. Any disruption on the legal front with regards to patents will 
have a negative effect. On the other hand, healthcare providers and their patients voiced 
their concerns that the current system limits the affordability and accessibility of 
healthcare. Patent protected drugs are often expensive, making it difficult for some 
patients to afford. In addition, these drugs have no generic counterparts and are often 
without alternatives, limiting their accessibility. The providers and their patients argue 
that relaxing the current regulations is needed and that doing so will not impact 
innovation. It is believed that increased competition will have a two-fold effect—driving 
down prices and forcing innovation as a means of differentiation. In the end, the 
decisions themselves have provided little guidance regarding how the biotechnology 
industry should proceed, but this much is clear—a balance needs to be struck between the 
two opposing viewpoints for the biotech industry to survive and continue to grow.
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 1 
INTRODUCTION 
 
Biotechnology is defined by the United States Department of State as “the use of 
modern scientific techniques, including genetic engineering, to improve or modify plants, 
animals, and microorganisms.” As an industry, biotechnology is defined not by its 
products but by a core set of enabling technologies—complex and sophisticated 
techniques such as gene splicing and polymerase chain reaction to name a few (Friedman, 
2008). Over time, it has continued to evolve as technology has advanced and our 
understanding of biology has expanded. Biotechnology now encompasses a wide range of 
applications including agriculture, industrial processes, and healthcare. While its 
definition has not changed drastically over time, we will be considering biotechnology as 
it applies to the manipulation of cellular and biomolecular processes. 
For the purposes of this paper, the focus will be on biotechnology’s impact on the 
field of medicine. During the 1970’s and 1980’s, traditional drug development was 
disrupted by an industry using new technology that harnessed the power of biological 
processes to develop drugs, vaccines, and diagnostic tests (Barfield & Calfee, 2007). In 
1982, Genentech produced the first recombinant DNA drug, human insulin, to be 
approved for marketing (Genentech Corporate Chronology). This milestone marks the 
beginning of the biotechnology industry as commonly thought of today. Since then, 
hundreds of drugs and diagnostic tests have been approved for use. And the continued 
advancement of the field has led to numerous breakthroughs in the field of medicine from 
cancer treatment to the detection of HIV. Table 1 lists just a few of those drugs along 
with their intended usage and the company responsible for their development. 
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Table 1. Biotechnology Drugs Approved for Use in the United States 
 
Trade Name Active Ingredient Year Approved Company Intended Usage 
Epogen Epoetin Alfa 1989 Amgen 
Used to treat anemia 
caused by chronic kidney 
disease, chemotherapy, or 
radiation therapy 
Rituxan Rituximab 1997 IDEC Pharmaceuticals 
Used to treat B-cell non-
Hodgkin lymphomas 
resistant to other 
chemotherapy regimens 
Herceptin Trastuzumab 1998 Genentech 
Used to treat metastatic 
breast cancer whose 
tumors overexpress the 
HER2 protein 
Humira Adalimumab 2002 Abbott 
Used to reduce signs and 
symptoms and inhibit the 
progression of structural 
damage in patients with 
rheumatoid arthritis 
Atripla 
Efavirenz; 
Emtricitabine; 
Tenofovir 
Disoproxil 
Fomarate 
2006 Gilead 
Used to treat HIV-1 either 
alone or in combination 
with other antiretroviral 
agents 
(Data obtained from http://www.accessdata.fda.gov/) 
 
 
As it has grown, the biotechnology industry has contributed not only to the United 
States economy but to the global economy as well. According a report by Ernst & Young, 
in 2010, there were 1,726 biotechnology companies in the United States with 315 of 
those public. Of the publically traded companies, their combined market capitalization 
was $292 billion (Ernst & Young, 2011). From 1992 to 2010, the revenues of the 
publically traded companies rose from a mere $8 billion to $61.6 billion (Ernst & Young, 
2011). The companies also employed over 100,000 people (Ernst & Young, 2011). These 
numbers do not even factor into consideration the agricultural and industrial companies 
engaged in biotechnology research and development nor the academic institutions that 
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are involved as well. Simply put, biotechnology and its supporting infrastructure play a 
significant role in the United States economy. 
The Ernst & Young (2011) report also indicates that the United States is the 
global leader in biotechnology. The United States dominates the rest of the world in 
every metric from number of companies and revenue to amount of capital raised. Upon 
further investigation, the reason for the United States’ dominance is twofold. First, the 
government contributes a significant amount of funding not only to support the 
biotechnology industry but also to support basic research in academia (Friedman, 2008). 
Second, strong intellectual property rights support and protect continued innovation 
(Friedman, 2008). In 1980, a combination of these two ideas gave rise to the Bayh-Dole 
Act. This act allowed for the licensing of patents emerging from federally funded 
research. Prior to its enactment, less than 5 percent of the 28,000 patents held by the 
federal government had been licensed and commercialized (United States General 
Accounting Office, 1998). Acting as a catalyst for the biotechnology industry, the Bayh-
Dole Act allows companies to license the discoveries made by academic research and 
translate them into commercial products capable of improving healthcare. Since then, the 
importance of intellectual property rights has been crucial to the growth and survival of 
the industry. 
A report by the Business and Industry Advisory Committee (BIAC) to the 
Organization for Economic Co-operation and Development (OECD) supports this claim, 
even singling out the healthcare sector as one that depends heavily on intellectual 
property. The report attributes advances in medicine to “strong and effective” intellectual 
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property rights (BIAC, 2004). It is the existence of such rights that promote the costly 
investments required to achieve breakthroughs (BIAC, 2004). Because it is so risky, the 
development costs can only be sustained if the “economic climate and policy framework 
support and reward successful [research and development]” (BIAC, 2004). Economically, 
it is beneficial to protect intellectual property rights because the downstream effect is the 
creation of “high-value” jobs (BIAC, 2004). And as the biotechnology industry grows its 
economic footprint, it has become increasingly important to protect the foundation upon 
which the industry is based. These companies “depend on [intellectual property] rights to 
raise capital efficiently, to create the foundation for sustainable and innovative business 
models, and to invest in highly risky new areas over an extended period of time” (BIAC, 
2004). 
As a result, companies go take every measure to protect their discoveries, with 
filing and securing patents and defending them in court if infringed upon. The cases of 
Mayo Collaborative Services et al. v. Prometheus Laboratories, Inc. (2012) and 
Association for Molecular Pathology et al. v. Myriad Genetics (2011) have been classical 
examples of how important it is to protect intellectual property rights at all cost.  
 
Bilski v. Kappos (2010) 
 To better understand how court decisions relating to patents are interconnected, 
we first discuss the case of Bilski v. Kappos (2010).   Though the case’s subject matter 
does not directly involve the biotechnology industry, the Bilski v. Kappos (2010) decision 
affects how subsequent cases are interpreted, including those in the biotechnology 
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industry such as Mayo Collaborative Services et al. v. Prometheus Laboratories, Inc. 
(2012). The key issue in Bilski v. Kappos (2010) dealt with the patentability of a method 
for hedging risk in the commodities market. Representing the United States Patent and 
Trade Office (USPTO), David Kappos denied the application on the grounds that “the 
invention is not implemented on a specific apparatus, merely manipulates an abstract 
idea, and solves a purely mathematical problem” (Bilski v. Kappos, 2010). The case’s 
relevance and importance to the biotechnology industry, however, lies in the decision. 
 The Supreme Court upheld the USPTO’s decision to reject the patent application, 
specifically addressing the machine-or-transformation test used by co-inventor Bernard 
Bilski to argue for the patent’s eligibility. For a process to be patent eligible under the 
“machine-or-transformation test”, it must be “tied to a particular machine or apparatus, or 
it transforms a particular article into a different state or thing” (Bilski v. Kappos, 2010). 
Notably, the decision states, “The machine-or-transformation test is not the sole test for 
patent eligibility” (Bilski v. Kappos, 2010). Instead, it is a “useful and important clue or 
investigative tool… for deciding whether an invention is a patent-eligible ‘process’” 
(Bilski v. Kappos, 2010). It also considers the challenges that the “Information Age” 
poses for patent law, stating “patent law faces a great challenge in striking the balance 
between protecting inventors and not granting monopolies over procedures that others 
would discover by independent, creative application of general principles” (Bilski v. 
Kappos, 2010). This challenge emerged out in the case of Mayo Collaborative Services et 
al. v. Prometheus Laboratories, Inc. (2012) and will continue to do so in future cases 
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involving the field of diagnostics, with many of the patents in this field covering 
processes. 
 
Referenced in Mayo Collaborative Services et al. v. Prometheus Laboratories, 
Inc. (2012), Bilski v. Kappos (2010) is evidence that decisions can have a broad impact 
and cases are often interconnected. The Federal Circuit referenced the “machine-or-
transformation” test from Bilski v. Kappos (2010) in its decision to uphold Prometheus’s 
patents. The importance of Mayo Collaborative Services et al. v. Prometheus 
Laboratories, Inc. (2012), however, lies with the patents in question and their pervading 
impact on the biotechnology industry. The case itself is unique because of how widely 
polarizing the case was. On one side, physicians expressed concern that patents such as 
the ones held by Prometheus would affect their ability to practice, just as Prometheus had 
interrupted Mayo’s clinical laboratory operations. On the other, biotechnology companies 
worried that a ruling in favor of Mayo would destabilize patent law and negatively impact 
the industry’s growth. 
Two such fields that stand to be affected are the field of diagnostics and the 
burgeoning field of personalized medicine—two of the biotechnology industry’s fastest 
growing concentrations. Broadly defined, the diagnostics industry provides analytical 
services that fill a variety of needs. These include but are not limited to clinical tests that 
aid in the diagnosis or detection of disease. The tests themselves range from everyday 
blood tests for glucose and cholesterol to more complex genetic and molecular testing. 
Personalized medicine is a relatively new industry brought about by advances in 
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technology and its application. Simply, it is the customization of healthcare, which 
focuses on the individual. And it is this customization that relies heavily on diagnostics. 
For example, a doctor can use the power of genetic testing to aid in diagnosis and then 
use it to screen drugs, determining which drug or drugs is the best treatment for a patient. 
Subsequently, the dosage can be tailored after administration by monitoring the drug or 
its metabolites to ensure maximum efficacy with minimal side effects. The promise of 
personalized medicine includes but is not limited to simultaneously improving patient 
care and outcome while reducing the cost burden on patients and providers. 
 
Mayo Collaborative Services et al. v. Prometheus Laboratories, Inc. (2012) 
 The case of Mayo Collaborative Services et al. v. Prometheus Laboratories, Inc. 
(2012) involves two laboratories, Mayo Collaborative Services and Prometheus 
Laboratories, which provide diagnostic testing. The dispute in this case revolves around 
two patents owned by Prometheus Laboratories, which cover the optimization of 
therapeutic dosage by sampling metabolite levels for the treatment of immune-mediated 
gastrointestinal disorders. The methods involved include the administration of the drug; 
determining the level of drug’s metabolites present in the patient’s system; and adjusting 
the dosage based on the measured levels. Initially, Mayo sent patient samples to 
Prometheus for testing. In 2004, however, Mayo announced its intention to sell and 
market a competing test based on very similar principles.  
 Prometheus subsequently sued Mayo for patent infringement. While the District 
Court found that Mayo did indeed infringe on the patents, it deemed the patents invalid. 
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The District Court reasoned that the correlation between the thiopurine metabolite levels 
in the body and levels of efficacy and toxicity claimed natural laws. As a result, the 
patents were invalidated and the court ruled in favor of Mayo. Subsequently, the case was 
appealed to the Federal Circuit where the District Court’s decision was reversed. Based 
on the machine-or-transformation test, Prometheus’s patents were declared valid. The 
case was appealed to the Supreme Court, but it was remanded in light of the Bilski v. 
Kappos (2010) decision. When a case is remanded, it is sent back to a lower court for 
reconsideration. In Bilski v. Kappos (2010), the Supreme Court held that the machine-or-
transformation test is not to be considered the sole test for patent eligibility. The case 
would eventually end up back in front of the Supreme Court. In a unanimous decision, 
the Supreme Court ruled in favor of Mayo Collaborative Services, invalidating the 
patents. Specifically, the court states that the patents’ subject matter covers a “law of 
nature” and thus is not patentable (Mayo v. Prometheus, 2012). In addition, the decision 
states that “a patent must do more than simply state the law of nature while adding the 
words ‘apply it’” as well as asserting the patent is too broad (Mayo v. Prometheus, 2012). 
In order for a law of nature to become patentable, there must be a transformative step but 
the patent uses methods that are “well known in the art” (Mayo v. Prometheus, 2012). 
According to the justices, the steps outlined in the patents were not sufficiently novel. 
 
As with Bilski v. Kappos (2010), the ramifications of the Mayo Collaborative 
Services et al. v. Prometheus Laboratories, Inc. (2012) decision will undoubtedly 
influence future rulings. For example, the Supreme Court remanded the Association for 
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Molecular Pathology et al. v. Myriad Genetics case following the Mayo Collaborative 
Services et al. v. Prometheus Laboratories, Inc. (2012) decision. While their patents do 
not overlap, they do both involve the biotechnology industry. As a result, members of the 
industry as well as parties that stand to be affected have a vested interest in the outcome 
of Association for Molecular Pathology et al. v. Myriad Genetics.  
 
Association for Molecular Pathology et al. v. Myriad Genetics 
 At the time of this writing, the case of Association for Molecular Pathology et al. 
v. Myriad Genetics (2011) has reached the Supreme Court for a second time. In this case, 
the plaintiffs are challenging the legality of the gene patents for BRCA1 and BRCA2—
otherwise known as breast cancer susceptibility genes. Mutations and specific variations 
in these genes have been linked to an increased risk of developing breast or ovarian 
cancer. The plaintiffs, including doctors, researchers, patients’ rights organizations, as 
well as organizations representing clinicians, also claim that they are unable to conduct 
BRCA-related activities because Myriad Genetics has been actively enforcing its patent 
rights. 
The case began in the District Court where the ruling invalidated all of Myriad’s 
patent claims. Myriad’s composition claims for the isolated DNA sequences of BRCA1/2 
were ruled invalid because they are not “markedly different” from native DNA, which is 
considered a product of nature (Association for Molecular Pathology v. Myriad, 2011). 
The method claims that relate to “analyzing” and “comparing” DNA sequences as well as 
for “comparing” cell growth rates were ruled invalid (Association for Molecular 
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Pathology v. Myriad, 2011). Subsequently, the case made its way to the Federal Circuit 
Court. There, the decision of the District Court was partially overturned by the Federal 
Circuit. Myriad’s patent claims involving isolated DNA and comparing cell growth rates 
were ruled patent eligible while the patent claims involving comparison of gene 
sequences remained invalid. The case then made its way to the Supreme Court where it 
was remanded in light of the Mayo Collaborative Services et al. v. Prometheus 
Laboratories, Inc. (2012) decision. The Federal Circuit Court reaffirmed its initial 
decision, and the case now finds itself back in front of the Supreme Court. 
 ______________________________ 
Specific Aims 
 For the purposes of this paper, we hope to find clues indicating how players in the 
industry as well as other affected parties believe diagnostics and personalized medicine 
will change. To do so, we will examine briefs filed in the both Mayo Collaborative 
Services et al. v. Prometheus Laboratories, Inc. (2012) as well as Association for 
Molecular Pathology v. Myriad (2011) to add context to reactions covered by the media. 
By reviewing articles published covering each case, we hope to assess how analysts and 
experts of the biotechnology industry believe personalized medicine will be affected. We 
will only briefly address the legal rhetoric that is being debated and instead concentrate 
on how the decisions made in each case will change personalized medicine. 
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PUBLISHED DATA 
 
 Recent and upcoming Supreme Court decisions regarding patentability and 
intellectual property will alter the landscape of diagnostics and personalized medicine. 
The question is how. Investigating briefs filed by invested parties in the following two 
cases provide clues into the effect of these decisions moving forward. 
 
Mayo Collaborative Services et al. v. Prometheus Laboratories (2012) 
 When Mayo v. Prometheus (2012) reached the Supreme Court, a multitude of 
amicus briefs were filed supporting the petitioners or the respondents and some 
supporting neither. The parties involved in the filing of these briefs are indication of the 
case’s importance. They range from large biotechnology firms such as Roche and 
Novartis to advocates of patients’ rights such as the American Civil Liberties Union and 
the AARP. And because it will “significantly affect” the work of the USPTO, the United 
States’ was compelled to file a brief outlining its position on the claims at issue (Mayo v. 
Prometheus, 2012). Judging by the number of interested and affected parties, the 
implications of any decision will be wide spread. 
 
Roche Molecular Systems, Inc., Ventana Medical Systems, Inc., Hoffman-La Roche 
Inc., and Abbott Laboratories, Inc. 
Roche and Abbott Laboratories are two companies that would be affected by the 
Court’s decision regardless of the ruling. They filed a brief that sides with neither the 
petitioners nor the respondent, attempting to strike a balance between the two sides. The 
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brief stresses the importance and potential of personalized medicine and the need to 
protect and incentive its advancement. Personalized medicine holds the potential to 
revolutionize how disease is diagnosed and treated. It promises to simultaneously 
improve patient care and reduce costs associated with health care (Mayo v. Prometheus, 
2012). To do this, diagnostic tests are used to detect specific biomarkers associated with 
disease can aid in initial diagnosis, prognosis, or assessing future risk. Patients can also 
be screened using diagnostic methods to determine the most appropriate treatment. 
Armed with more information, the accuracy of diagnosis and treatment will increase, 
decreasing health care costs in turn, and less money will be spent on needless tests or 
treatments.  
Combined, the two companies invest billions in the research and development of 
medical diagnostic products and technologies, the core of personalized medicine. From 
their perspective, patent protection safeguards against “free-riding” and incentivizes 
innovation in areas that “hold the greatest promise for improving treatment and 
decreasing the costs of therapy for those suffering from often fatal diseases” (Mayo v. 
Prometheus, 2012). In other words, existing patent protection encourages the investment 
required to commercialize inventions (Mayo v. Prometheus, 2012). The discovery and 
validation of clinically useful biomarkers is not only expensive, but also just one of many 
hurdles to commercial success. Regulators, insurers, and clinicians must all be convinced 
of the diagnostic test’s utility before it even reaches a single consumer. At the same time, 
it is important to remember that exclusivity is only for a limited period of time and is 
considered to be a “necessary incentive” (Mayo v. Prometheus, 2012). But because not 
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all investments pan out, those that are successful must turn enough of a profit to cover the 
cost of the failures. This is an important consideration given that companies must have a 
sustainable business model to be successful. Should diagnostic correlations be ruled 
invalid, the profit margins of the diagnostics industry will shrink. And if the profits of the 
few successful products are diminished, the amount of money and resources available to 
reinvest will also decrease. Companies may become more careful and cautious when it 
comes to making investments. It is, however, often the more radical ideas that turn out to 
be revolutionary. Innovation is not the incremental improvement of existing systems and 
cannot be achieved by simply making the safe bets. 
 While the brief does not address Prometheus’s patents and their validity, it does 
lean heavily in favor of maintaining the current patent protection that personalized 
medicine enjoys. Even so, an attempt is made to offer alternatives and address the fears 
of the petitioners. For example, the petitioners fear that upholding such patent protection 
may stifle innovation and basic science research. In the brief filed by Roche and Abbott, 
however, multiple sources are cited indicating that this has yet to happen. In a report by 
the Federal Trade Commission titled Emerging Health Care Issues, the report reveals that 
“patents do not inhibit research leading to new discoveries and, in fact, may in some 
cases stimulate it through the disclosure of innovations” (Federal Trade Commission, 
2009). Because these discoveries have been patented and protected, companies are more 
likely to share because they are protected from copycats (Mayo v. Prometheus, 2012). 
Specifically addressing the growth and future of personalized medicine, Roche and 
Abbott believe that a key barrier is the “lack of clear regulatory guidelines for approval of 
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molecular diagnostics and the failure of insurers to provide standardized coverage criteria 
for diagnostic testing” (Mayo v. Prometheus, 2012). Moving to address worries that 
patents will restrict patient access to testing, the brief states: “the incentive to inform the 
public about patented diagnostic products creates a social benefit by improving access 
and creating awareness among at-risk individuals” (Mayo v. Prometheus, 2012). Even 
though exclusivity gives companies pricing power, they must be careful not to price 
themselves out of the market (Mayo v. Prometheus, 2012). A temporary monopoly means 
nothing if no one is willing to pay. Even before all this, an important question is raised: 
“Would [an] invention exist if it were unpatentable?” (Mayo v. Prometheus, 2012). The 
argument here is that without adequate incentives and protection, there would be no 
compelling reason for diagnostics companies to continue research and development. It is 
possible that underlying basic science research may continue, but no company would be 
willing to commercialize any discoveries. To address any potential issues pertaining to 
patient access, the authors of the brief suggest collaborative licensing agreements or even 
the pooling of patents instead of a “blanket declaration of patent ineligibility” (Mayo v. 
Prometheus, 2012). In supporting neither party, the brief attempts to assuage the concerns 
of both parties while encouraging the court to consider all view points before rendering a 
decision. 
 
ARUP Laboratories, Inc. and Laboratory Corporation of America Holdings 
 Associated Regional and University Pathologists Laboratories, Inc. (ARUP) and 
Laboratory Corporation of America Holdings (LabCorp) jointly filed a brief in support of 
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Mayo. Their argument is that Prometheus has patented laws of nature and that the patents 
themselves “involve no such transformation and seek to preempt all use by others of a 
basic natural phenomenon” (Mayo v. Prometheus, 2012). The two laboratories are 
concerned with the ramifications of upholding Prometheus’s claims, believing such a 
decision would negatively impact research and in turn, patient care. In their eyes, the 
patent protection grants Prometheus the power to exclude, precluding the contents of the 
patents from further scientific inquiry. Ultimately, it would “remove the common tools 
accessible to all scientists that allow scientific progress to be made,” particularly because 
scientific discoveries build upon one another (Mayo v. Prometheus, 2012). Supporting 
the invalidation of the patents, the brief calls upon precedents set in previous cases. It 
argues that the invalidation of the patents held by Prometheus would be sufficiently 
narrow enough that it would not affect patents that “involve more than the mere 
observation and recitation of a law of nature” (Mayo v. Prometheus, 2012). The two 
laboratories are confident that inventors and companies will continue to file patents for 
novel discoveries that are truly transformative (Mayo v. Prometheus, 2012). 
 In examining the background of both ARUP and LabCorp, the motivations for 
siding with Mayo become evident. Both are clinical testing laboratories whose businesses 
rely, in part, on performing diagnostic tests. And the Supreme Court’s decision to 
invalidate Prometheus’s patents supports their cause. Now, both labs can access a market 
they were previously barred from entering. But being in the diagnostics business as well, 
the laboratories supported a narrow decision in their brief—one that will not affect their 
own patents. An examination into recent patents granted to ARUP reveals that they cover 
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processes that improve upon current diagnostic technology. It is reasonable to assume 
that these patents are not affected by the decision, though things may have been different 
if the patents covered diagnostic correlations. In 1999, Metabolite, Inc. sued LabCorp for 
infringement of a patent that covered correlations between homocysteine and vitamins B6 
and B12. Though the Supreme Court did not render a decision, the lower courts 
maintained that Metabolite’s patent is valid. In supporting Mayo, LabCorp would like to 
see a decision by the Supreme Court regarding the patent eligibility of natural phenomena 
and laws of nature. Both ARUP and LabCorp rely on this scientific knowledge and 
believe that the removal of such knowledge from the public domain negatively impacts 
their business (Mayo v. Prometheus, 2012). While ARUP is a non-profit organization and 
LabCorp is a business, it is still interesting to note that the brief does not address the 
monetary aspect of performing research. 
 
National Venture Capital Association 
 Many other interested parties, those that supported Prometheus in particular, also 
voiced their concern. They fear that should the patents be invalidated, the fallout would 
be far-reaching. One such party is the National Venture Capitalists Association (NVCA). 
The organization represents venture capitalists and their interests, “advocating for 
policies that encourage innovation and reward long-term investment” (Mayo v. 
Prometheus, 2012). It is the opinion of the NVCA that the ability to obtain funding to pay 
for research and development of new tests will become increasingly difficult if patent 
eligibility for diagnostic correlations is removed (Mayo v. Prometheus, 2012). As a 
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result, the growth of personalized medicine will be severely stunted, negatively affecting 
current and future investments (Mayo v. Prometheus, 2012). Many personalized medicine 
companies rely on venture backing to test and validate their ideas. There is, however, a 
high failure rate, which has prompted venture capitalists to seek ways to mitigate the risk. 
And one of these ways is patent protection. To support their point of view, the NVCA 
cites successful companies, such as Genomic Health, Inc., that have emerged as a result 
of venture capital funding as well as stressing the economic impact, such as job creation, 
that the personalized medicine industry has and can make. 
 The NVCA brief also attempts to assuage concerns should the patents be upheld. 
Citing a report titled Patents, Material Transfers, and Access to Research Inputs in 
Biomedical Research, the association notes that in reality, patents have a minimal if not 
negligible effect on research and does not stifle innovation (Walsh, Cho, & Cohen, 2005). 
In addition, the NVCA believes that the patents have been oversimplified and are not 
actually laws of nature. Instead, the patents cover “very specific complex 
interrelationships between a multitude of biological markers and their correlation with 
specific diseases,” and their validation is the “product of human innovation” (Mayo v. 
Prometheus, 2012). As such, these patents and similar works do not preempt nature. 
 In this case, the interests of the NVCA are very clear. If the personalized medicine 
industry continues to grow, their members stand to profit. Investing in biotechnology 
companies is not without risks, and patent protection is considered a way to counter-
balance this risk. The removal of such protection removes an incentive to continue 
investing and puts current investments at risk. As it pertains to this case, diagnostics are 
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considered by the NVCA to be a “core segment” of personalized medicine (Mayo v. 
Prometheus, 2012). They are concerned that the negative impact of invalidating patents 
covering diagnostic correlations will severely hamper the growth and potential of this 
emerging market. And in light of the decision by the Supreme Court to invalidate 
Prometheus’s patent claims, the venture capitalists that have already invested in 
diagnostics companies have suddenly assumed more risk. Without the guarantee of 
exclusivity, these companies will find it more difficult to achieve profitability, 
simultaneously making it more difficult for investors to receive a sizable return. The key 
incentive to invest in personalize medicine removed, the NVCA’s members will likely 
further reduce their investments in diagnostic companies, severely hampering the growth 
of personalized medicine (Mayo v. Prometheus, 2012). As referenced in the brief, there 
will also be a ripple effect through the economy—including job creation and economic 
growth (Mayo v. Prometheus, 2012). The current and continued uncertainty surrounding 
patents and diagnostic companies has cause a decrease in investments, and the ruling 
invalidating diagnostic patents with no transformative step means the trend will continue 
if not accelerate. 
 
Genomic Health, Inc., Veracyte, Inc., XDX, Inc., Biodesix, Inc., Target Discovery Inc., 
The Coalition for 21st Century Medicine, and Baybio 
 The previous NVCA brief mentions Genomic Health as one of the success stories 
of personalized medicine. The company must be able to reinvest in continued advances in 
order to sustain its success and patent protection of its discoveries helps safeguard the 
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profits to do so. As a result, Genomic Health filed a brief in conjunction with additional 
personalized medicine companies and organizations in support of Prometheus. The 
companies and organizations represented are heavily involved in the future of the 
personalized medicine industry. Many of the companies are focused on diagnostics; 
hence, they have a vested interest in seeing patent protection for diagnostic correlations 
upheld. In their eyes, “the patent system is essential to protect and drive biomedical 
innovation because it is the protection from copying for novel diagnostics that attract 
financial investment” (Mayo v. Prometheus, 2012). Even though the tests themselves are 
easily imitated, they contend that the discovery and verification of the correlations are not 
only costly but also complex (Mayo v. Prometheus, 2012). Only after the correlations 
have been supported by research, do they seem self-evident (Mayo v. Prometheus, 2012). 
Regulatory and reimbursement hurdles are next on the path to commercialization (Mayo 
v. Prometheus, 2012). Factor in the challenge of educating clinicians and convincing 
them to adopt new procedures and the degree of difficulty to launch a successful product 
increases (Mayo v. Prometheus, 2012). The continued success of personalized medicine 
promises to upset the profitability of the current status quo. On the other hand, it has the 
potential to save both patients and the healthcare system time and money (Mayo v. 
Prometheus, 2012). The brief paints Mayo and its supporters as resisting change because 
they stand to profit should the patents be ruled invalid (Mayo v. Prometheus, 2012). 
Conversely, should Prometheus’s patents be overturned, the private funding that 
personalized medicine relies so heavily on will dry up. Without the exclusivity provided 
by patents, investors will be more hesitant because it will become increasingly difficult to 
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recoup their investments. The current challenges stemming from reimbursement and 
regulation have already made investors weary, leading to decreased investment in 
diagnostic companies (Mayo v. Prometheus, 2012).  
 With the Supreme Court having decided the case in favor of Mayo, Genomic 
Health and its fellow personalized medicine companies face an ever more challenging 
battle to advance their industry. Primarily, the patent protection that once guaranteed 
exclusivity has been called into question. This opens up the core of their business to 
increasing competition, affecting revenue. Would be investors will now take an even 
closer look at patent portfolios and become even more hesitant to invest in companies 
whose core businesses are diagnostics (Mayo v. Prometheus, 2012). Additionally, 
companies currently focused on diagnostics may consider moving away from a business 
that now seems uncertain. With less attention on diagnostics, the growth of the fledgling 
personalized medicine industry will undoubtedly slow. It is, however, not only the 
industry that suffers. The promise and potential of personalized medicine to improve 
patient care and reduce cost will be put on hold. 
 
Cato Institute, Reason Foundation, and Competitive Enterprise Institute 
 In filing a brief in support of Mayo, the Cato Institute, Reason Foundation, and 
Competitive Enterprise Institute (CEI) believe that patent enforcement will have a 
different effect and filed a joint brief detailing their views on the matter. All three 
institutes promote free market economics whereby supply and demand dictate pricing and 
the direction of the market. Based on those principles, the institutes argue that patents 
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have a “net negative effect in most industries,” specifically patents that are broad and 
abstract (Mayo v. Prometheus, 2012). In Of Patents and Property, Bessen and Meurer 
challenge the notion that patent protection encourages innovation and investment (Bessen 
& Meurer, 2008). Instead, companies have historically “set up patent pools that may have 
substantially extended their market power and posed entry barriers or disincentives to 
other innovators” (Mayo v. Prometheus, 2012). While it is acknowledged that chemical 
and pharmaceutical firms have achieved a positive return on investment thanks to patent 
protection, the brief focuses on the technology industry’s software related patents to 
make their case (Mayo v. Prometheus, 2012). To start, the patent archives are difficult to 
search, making it a challenge for firms to establish if their current work infringes on 
existing patents (Mayo v. Prometheus, 2012). Conducting a search may also reveal 
numerous patents covering very similar material, further muddying the waters (Mayo v. 
Prometheus, 2012). The filers of this brief believe that combined, this is a large enough 
hurdle that discourages investment and in turn, innovation. Additionally, many 
companies spend a sizeable amount of money obtaining patents for defensive purposes, 
hoping to discourage litigation. In the technology sector, the large number of patents 
covering software has contributed to a higher chance of infringement and in turn, costly 
litigation. The brief argues that “these firms will wind up in the same competitive 
position they would have been in had the patents never [been] issued—free to compete 
against each other in the market without regard to patents—at a cost of billions of 
dollars” (Mayo v. Prometheus, 2012). This is money that could have been spent on 
products and research and development, among other things (Mayo v. Prometheus, 
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2012). It is feared that what has since happened to the software industry will result in a 
similar outcome for medical diagnostics (Mayo v. Prometheus, 2012). Perhaps the 
greatest consequence should the patents be upheld is the removal of existing knowledge 
from the public domain. It is believed that “access to patented knowledge places 
individuals in situations where they must elect to cease doing what was previously a 
public domain activity… or inadvertently infringe a patent” (Mayo v. Prometheus, 2012). 
 The focus of the brief has been on drawing parallels between the medical 
diagnostics industry and the software industry, warning that the legal battles have 
detracted from advances made. No attempt is made, however, to compare the medical 
diagnostics industry with the pharmaceutical industry, arguably a closer comparison. 
With the Court deciding to side with Mayo, the fears of the Cato Institute, Reason 
Foundation, and CEI will not come to pass—at least not in the same way. Though it can 
be considered a “win” for the free-market, the opinions expressed by those in the industry 
suggest that innovation will slow and investment will decrease. Specifically, personalized 
medicine companies such as Genomic Health and biotechnology companies such as 
Roche have stated in briefs of their own that without patent protection, their investment 
in furthering medical diagnostics will decrease. While important concerns are raised, it is 
important to keep in mind the position of those actually in the industry. Coupled with a 
decrease in venture capital funding noted by the NVCA, it is difficult to accept that 
innovation will not slow (Mayo v. Prometheus, 2012). The end result is a lower barrier of 
entry but no sources of funding. 
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Novartis Corporation 
 As a public firm involved in pharmaceuticals as well as medical diagnostics, 
Novartis Corporation’s brief in support of Prometheus opposes some of the arguments 
made by the Cato Institute and its co-petitioners as well as presenting a few of its own. 
Novartis states that “absent an ability to protect its investments with valid patents, 
healthcare companies like [itself] would lack the necessary incentive to make the 
extraordinary financial outlays required to bring medical innovations to market” (Mayo v. 
Prometheus, 2012). Central to Novartis’s argument is the patent-eligibility of therapeutic 
and diagnostic processes under Section 101 of the Patent Act (Mayo v. Prometheus, 
2012). As this relates to personalized medicine, the concern is that research into the 
interrelationships between genes and diseases would be curtailed without patent 
protection. Admittedly, Novartis states, “Although driven by the desire to improve 
healthcare, the prospect of patent protection also provides an important incentive to 
expend—and the necessary protection to fund—the time and effort necessary to make 
biomedical discoveries and translate them into new medical procedures that help 
patients” (Mayo v. Prometheus, 2012). This includes not only correlations that predict 
diseases but also ones that predict response to treatment. In many cases, these discoveries 
are “novel and non-obvious biomarkers, without which the benefits they unlock would 
remain hidden” (Mayo v. Prometheus, 2012). It is also worth consideration that the 
reason litigation costs are so high is because companies such as Novartis go to great 
lengths to protect their investments. Removal of such a critical incentive and product 
exclusivity would negatively affect the company’s bottom line.  
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Should Prometheus’s patents be upheld, it stands to reason that the discoveries 
stemming from the Human Genome Project will continue to yield improved medical 
treatments (Mayo v. Prometheus, 2012). Tools are being developed to detect, treat, and 
prevent disease based on the research being done to decipher the complex 
interrelationships between specific genes and diseases (Mayo v. Prometheus, 2012). 
Without a disruption on the legal front with regards to patents, the advancement of 
personalized medicine and diagnostics, Novartis believes, can continue to accelerate. 
 Now that the court has sided with Mayo and invalidated Prometheus’s patents, 
however, Novartis must now reconsider its allocation of resources in medical diagnostics. 
The patent protection previously afforded to Novartis with regards to diagnostic assays 
has been jeopardized, and the incentive to continue research and development in this and 
similar fields has significantly diminished. Interestingly, Novartis also provides 
additional insight into the economic importance and potential downstream effects of such 
a decision. Before the Supreme Court rendered its decision, Novartis made the decision 
to spend $600 million to expand its presence in Cambridge, Massachusetts (Mayo v. 
Prometheus, 2012). In light of the decision, Novartis’s investment in Cambridge is 
negatively impacted because it will be more difficult for the divisions investigating 
medical diagnostics to add sustainable and substantial value to the company. Research 
operations, partnerships with local universities, and biotechnology start-ups all stand to 
lose if Novartis chooses to shrink its footprint in response (Mayo v. Prometheus, 2012). 
The potential economic impact will be great if Novartis and similar companies to scale 
back research in affected fields and reduce jobs. Unfortunately, this trend has already 
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begun in venture capital, with less money being invested in medical diagnostics and 
consequently less jobs being created in a potentially high growth field (Mayo v. 
Prometheus, 2012). 
 
Myriad Genetics 
 Perhaps most interesting of the briefs filed in Mayo Collaborative Services et al. 
v. Prometheus Laboratories, Inc. (2012) is the brief filed by Myriad Genetics. While the 
contents of the brief do not stand out, it is Myriad’s predicament that is of interest. At the 
time of this writing, Myriad is being sued by the Association for Molecular Pathology 
and other parties over the right to patent the genes BRCA1 and BRCA2. As a player in 
the field of personalized medicine, Myriad has an obvious interest in the case’s outcome. 
But more importantly, the outcome of the case stands to impact their ongoing case. 
Specifically, Myriad is worried about the fallout should Prometheus’s patents be deemed 
invalid on the grounds that they cover “laws of nature” (Mayo v. Prometheus, 2012). A 
broad interpretation of such a decision will lead to questions surrounding patentable 
material and what constitutes laws of nature. And every patent can ultimately be linked to 
some natural phenomenon or law of nature. This creates a slippery slope, ultimately 
challenging the validity of Myriad’s various patents. 
In siding with Prometheus, Myriad is not only looking out for the interests of the 
biotechnology industry but also its own immediate interests. Much like the other parties 
who sided with Prometheus, Myriad argues that the immense potential of personalized 
medicine is jeopardized if there is not adequate patent protection to incentivize research 
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in the field. Both patient and provider stand to benefit from the lower costs that 
integrating personalized medicine promises. Just like the pharmaceutical industry, 
however, personalized medicine research and development is costly and has a low rate of 
success (Mayo v. Prometheus, 2012). Clinical trials are required to “demonstrate the 
clinical utility of the discovered correlation,” and they are “essentially equivalent” to 
pharmaceutical trials, making them lengthy, complex, and expensive (Mayo v. 
Prometheus, 2012). While personalized medicine and pharmaceuticals share many of the 
same challenges, Myriad argues that personalized medicine is at an even greater 
disadvantage. Not only is there a smaller potential payoff, but there is also a regulatory 
environment that makes it difficult for companies to protect their inventions (Mayo v. 
Prometheus, 2012). In response, broader patent claims are drafted when it comes to the 
diagnostic use of correlations, like those outlined in Prometheus’s patents. By examining 
a patent, it’s possible for a competitor to “make trivial changes to the innovator’s 
diagnostic process, piggyback on the innovator’s clinical studies, and merely validate the 
technical aspects of the laboratory to satisfy CLIA requirements” (Mayo v. Prometheus, 
2012).  
 Myriad worries that invalidation of Prometheus’s patents will destroy a nascent 
personalized medicine industry. The brief focuses on “incentivizing personalized 
medicine products” in the wake of the information made available as a result of the 
Human Genome Project (Mayo v. Prometheus, 2012). The Human Genome Project has 
facilitated the discovery of new correlations but has also “simultaneously made patenting 
in personalized medicine much more challenging, because human genes have been 
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elucidated and virtually all proteins encoded by these genes are now known to the public” 
(Mayo v. Prometheus, 2012). Myriad believes it is critical to “incentivize the discovery of 
new correlations and the development of the use of such correlations into commercial 
personalized medicine products” (Mayo v. Prometheus, 2012). With the Court choosing 
to side with Mayo, the incentive for continued investment in personalized medicine is 
jeopardized. This not only puts a damper on the growth of personalized medicine but also 
the innovation that stems from the discovery of new correlations. One of the reasons is 
competitors are forced design around existing patents, looking for new pathways and 
correlations in the process. If the industry moves away from disclosing and patenting 
discoveries, the motivation to discover new correlations and develop better diagnostic 
tests decreases. 
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Association for Molecular Pathology et al. v. Myriad Genetics 
 While we will not speculate on the outcome of Association for Molecular 
Pathology et al. v. Myriad Genetics (2011), examining briefs filed in favor of both 
petitioners and respondents will provide clues as to what the future holds. Initially, the 
District Court invalidated all of Myriad’s claims relating to isolated DNA sequences and 
various diagnostic correlations. Subsequently, the Federal Circuit chose to uphold the 
patent eligibility of gene patents and specific diagnostic claims while invalidating others. 
The case had previously reached the Supreme Court but was remanded in light of the 
Mayo Collaborative Services et al. v. Prometheus Laboratories, Inc. (2012) decision. At 
the time of writing, the Federal Circuit has confirmed its original ruling, sending the case 
back to the Supreme Court. As a result, the most recent briefs submitted to the Supreme 
Court either argued for the case to be remanded to the Federal Circuit or that the decision 
handed down in Mayo Collaborative Services et al. v. Prometheus Laboratories, Inc. 
(2012) does not apply. Consequently, we will primarily be examining briefs from when 
the case first appeared before the Federal Circuit Court in 2011. 
 
AARP (American Association of Retired Persons) 
 In the case of Association for Molecular Pathology et al. v. Myriad Genetics 
(2011), the AARP has filed a brief to the Federal Circuit Court arguing for the decision 
made by the District Court to be upheld. The ruling handed down by the District Court 
invalidated so-called “gene patents.” When considering potential ramifications, it is 
important to keep in mind that the mission of the AARP is to promote the “availability of 
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quality and economical health coverage” for people age fifty and older (Association for 
Molecular Pathology v. Myriad, 2011). Appropriately, the AARP is concerned with how 
the cost of genetic testing affects its availability as well as how patents affect the rights of 
patients to seek a second opinion. 
 Because genetic testing is a relatively new field, problems with insurance 
coverage and education remain. Patents grant exclusive rights to their holders and as a 
result the price for a genetic test exclusive to a single company can be high. From the 
perspective of the AARP and its constituents, this puts genetic testing out of reach for 
many individuals who would otherwise benefit. Many of those represented by the AARP 
rely on Medicare for health insurance, where coverage for genetic testing is limited 
(Association for Molecular Pathology v. Myriad, 2011). The way it is currently set up, 
genetic testing is only covered after an individual has been diagnosed with cancer. This 
completely nullifies the potential benefit of actively prescreening patients and does not 
maximize the potential to lower the cost of health care. 
 Meanwhile, the role of genetic testing has slowly increased—influencing and in 
some cases guiding medical diagnoses and decisions. With a higher profile role, it is 
important that these tests are accurate and up to date. In a study conducted in 2002, 300 
individuals who received a negative Myriad BRACAnalysis test result were studied over 
the course of three years (Walsh et al., 2006). It was found that 35 of the 300 individuals 
carried a previously undetected BRCA1/2 mutation that was not detected by Myriad’s 
test at the time (Walsh et al., 2006). Because breast cancer and ovarian cancer are 
considered very dangerous, patients who receive negative results must often decide 
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whether or not to have a mastectomy or other invasive surgery. This is a difficult decision 
that should not be taken lightly, and the AARP believes that “individuals seeking any 
type of genetic testing should have the option of securing a second opinion which can 
have life altering results” (Association for Molecular Pathology v. Myriad, 2011). The 
ability to seek a second opinion, however, is not limited to patients. It also applies to 
laboratories looking to confirm unexpected results. Yet the ability to do so is unavailable 
when only one patent-enabled provider exists. Furthermore, the need to get a second 
opinion is reinforced by the “limited governmental oversight over genetic tests” 
(Association for Molecular Pathology v. Myriad, 2011). There is no way to determine a 
lab’s proficiency without developing standards or benchmarks in conjunction with 
multiple labs (Association for Molecular Pathology v. Myriad, 2011). This need for 
increased guidance has been mentioned on multiple occasions in briefs filed in Mayo 
Collaborative Services et al. v. Prometheus Laboratories, Inc. (2012).  
As it currently stands in 2012, the Federal Circuit has upheld the patent eligibility 
of Myriad’s patents for the breast cancer susceptibility genes BRCA1 and BRCA2. With 
this ruling, the concerns of the AARP will continue to persist. Genetic testing performed 
is reliant on gene patents such as those held by Myriad. For example, Myriad’s 
BRACAnalysis test looks for mutations in BRCA1/2 that correlate with an increased risk 
of breast or ovarian cancer. Should a mutation be found, preventive measures specific to 
the individual can then be taken. This is just one of the promises of personalized 
medicine. There is also the potential to lower the total cost of health care and decrease the 
burden on the health care system. The concerns of the AARP, however, are both valid 
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and very real. The monopoly guaranteed to the patent holder gives them the power to 
price their test. And because breast and ovarian cancer can both be devastating diseases, 
the price the market will bear is very high given the alternative—death. Following the 
AARP’s line of reasoning, the cost of genetic tests such as Myriad’s is tied to the 
accessibility of the test. The higher the cost, the harder it is to access. As it pertains to 
BRCA1/2 and perhaps others as well, the high cost acts as a barrier, excluding many of 
the ACLU’s constituents who are on Medicare. While Medicare covers screening for 
those who have already contracted cancer, it does not currently cover prescreening 
(Association for Molecular Pathology v. Myriad, 2011). Medicare beneficiaries are out of 
luck unless they wish to pay for these tests out of pocket, which can be very expensive 
(Association for Molecular Pathology v. Myriad, 2011). It is important, however, to 
remember that patents do expire, eventually allowing other laboratories to begin 
performing the same tests. But by the time patent exclusivity expires, it will be too late 
for some. One of the reasons personalized medicine is so exciting and promising is its 
potential to reduce the burden of healthcare—both for the provider and the patients. The 
high cost may also slow adoption rate, with practitioners hesitant to order tests that their 
patients cannot pay for. Combined with the inability to seek a second opinion if 
necessary, the acceptance of genetic testing by the public and practitioners faces many 
hurdles, regardless of utility. 
 
Rosetta Genomics, Ltd., Rosetta Genomics, Inc., and George Mason University 
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 In opposition to the invalidation of the patents, Rosetta Genomics and George 
Mason University filed a joint brief supporting Myriad. The core business of Rosetta 
Genomics is the development of cancer diagnostic tests, which would benefit from patent 
protection. George Mason University, on the other hand, is an academic institution 
concerned about the future of the patents they own covering cancer diagnostics. Both 
parties are concerned that “a decision against subject matter patentability by this court 
would significantly undermine biotechnology innovation” (Association for Molecular 
Pathology v. Myriad, 2011).  
 Like many of those in the industry, both parties believe that overturning and 
invalidating all gene-related patents will not promote innovation. Though they are willing 
to admit that invalidation could stimulate some additional basic research, translational 
research almost certainly will be negatively affected (Association for Molecular 
Pathology v. Myriad, 2011). The existence of the patent system allows for the transfer of 
basic research conducted at academic institutions to the biotechnology industry. It is at 
these for-profit institutions within the industry that most translational research takes place 
because they have the money and the knowhow to successfully bring a product to market 
(Association for Molecular Pathology v. Myriad, 2011). Like many of the companies that 
voiced their support for Prometheus in Mayo Collaborative Services et al. v. Prometheus 
Laboratories, Inc. (2012), the parties that filed this brief believe that patent protection is a 
necessity. The patent system provides a period of exclusivity from which companies and 
investors hope to recoup their investments as well as securing funding for future projects 
(Association for Molecular Pathology v. Myriad, 2011). Without this protection, the 
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initial innovator stands to take a significant financial loss once copycats enter the market 
(Association for Molecular Pathology v. Myriad, 2011). In the worst case, existing 
companies that rely heavily on their diagnostics business may be forced to shut down. 
Sustaining continued innovation will become increasingly difficult—raising money from 
investors will become more difficult and revenue will decrease significantly with 
increased initial competition (Association for Molecular Pathology v. Myriad, 2011). It is 
uncertain if academic institutions can acquire the expertise to take basic research and 
advance it beyond the initial stages of translational research and development. On the 
other hand, those in academia have acknowledged “the ability of universities to obtain 
and manage gene patents has a profoundly positive impact on innovation” (Association 
for Molecular Pathology v. Myriad, 2011). Even with the existence of patents, the fact 
that they are published means that workarounds can be developed from the information 
provided. 
Should the Supreme Court affirm the District Court’s decision, the future of 
personalized medicine may yet be realized. Basic research conducted by academic 
institutions may be largely unaffected with over 7000 papers published linked to 
BRCA1/2 (Association for Molecular Pathology v. Myriad, 2011). If the trend holds, 
academic research will likely be allowed to continue without interference from patent-
holding commercial entities. How the focus of research will change will depend largely 
on the situation and the individual researchers. The invalidation of diagnostic 
correlations, however, will hurt the industry, but the ability to patent isolated genes 
provides and outlet. Patent protection will continue to encourage continued investment 
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and innovation, at least for genes. It’s plausible that Myriad’s patents on BRCA1/2 will 
continue to limited translational research and development of commercial products, but 
once the patent expires, others will be free to enter the market. The impact on Rosetta 
Genomics’ is uncertain because the court did not provide specific guidance pertaining to 
diagnostic tests isolated nucleic acid sequences. 
 
Universities Allied for Essential Medicines 
 Lead by students, the Universities Allied for Essential Medicines (UAEM) is a 
nonprofit organization that promotes innovation and affordable access to health-related 
technologies—particularly those developed from university research (Association for 
Molecular Pathology v. Myriad, 2011). This is an important consideration that is not 
addressed by many. Research conducted using public funds by academic institutions is 
frequently licensed to firms hoping to commercialize the findings. The UAEM supports 
increased access to this research as well as any products it helps create (Association for 
Molecular Pathology v. Myriad, 2011). Of the existing gene patents, two thirds of them 
are the result of public funding while more than a quarter are owned by universities 
(Association for Molecular Pathology v. Myriad, 2011). The UAEM believes that gene 
patents stifle research because genes are removed from the public domain (Association 
for Molecular Pathology v. Myriad, 2011). Fittingly, the organization supports the 
District Court’s decision to invalidate both Myriad’s gene patents and diagnostic claims. 
 The primary concerns of the UAEM relate to how patents like those held by 
Myriad hinder the progress of science and how patients are ultimately affected. On 
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multiple occasions, gene patents have been found to discourage continued research. For 
example, a study conducted in 2009 found that thirty percent of clinical laboratories 
voluntarily ceased development on a diagnostic test for a hemochromatosis-related gene 
once it was patented (Herder, 2009). Part of the reason for this is because gene patents 
such as those covering the genes BRCA1/2 are said to “completely foreclose research on 
any effects of the BRCA1/2 genes” (Association for Molecular Pathology v. Myriad, 
2011). The power granted Myriad, holder of these patents, is immense. And because the 
patent holder wields such power, it has impacted research activities related to patented 
genes. Any research conducted that is in any way related to BRCA1/2 infringes on 
Myriad’s patents. Understandably, clinical laboratories and researchers are weary of 
conducting research that infringes on patents. Furthermore, it is important to remember: 
“[A patent] grants the patent holder the right to exclude others from making, using, 
selling, offering for sale, or importing the invention, for a term of 20 years from the date 
of filing of a patent application” (Secretary’s Advisory Committee on Genetics, Health, 
and Society, 2010). 
The exclusivity and temporary monopoly granted by patents is a double-edged 
sword. Patents provide companies a reason to invest in research and development plus 
protect these investments. On the other hand, “a patent does not allow or compel a patent 
owner to take any action whatsoever—including using the technology themselves” 
(Secretary’s Advisory Committee on Genetics, Health, and Society, 2010). An 
examination of Myriad’s BRCA1/2 tests found that the test had a 12% error rate in 
correctly finding mutations (Walsh et al., 2006). The test also fails to detect up to 20% of 
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known BRCA1 mutations (Benowitz, 2002). Because Myriad has been granted a period 
of exclusivity and maintain a monopoly on the market, there is no reason for them to 
continue to spend additional resources on the continued improvement of the existing test. 
While this appears to be a good business decision, it is the patients that ultimately suffer. 
As the exclusive test on the market, it is very difficult if not impossible for patients to 
seek a second opinion based on a different BRCA test (Association for Molecular 
Pathology v. Myriad, 2011). 
 The UAEM contends that the end result of Myriad’s patent exclusivity is a 
“decrease in information concerning these genes because further research results cannot 
be made publicly available due to Myriad’s issuance of cease-and-desist letters to 
scientists and decision to preclude all research into these genes” (Association for 
Molecular Pathology v. Myriad, 2011). If the Supreme Court chooses to uphold the 
Federal Court’s ruling, the concerns raised by the UAEM will go unaddressed. Even if 
Myriad chooses not to sue organizations conducting research on the BRCA1/2 genes, 
they still ultimately control the utility of any findings. Should any discoveries pose a 
threat commercially, Myriad can use patents to protect their own interests. The Federal 
Court has also declared some diagnostic correlations invalid, potentially opening up the 
field to additional competitors. But because Myriad holds the gene patent for BRCA1/2, 
the company will be able to halt the usage of any competing test because it will be 
infringing on the existing gene patent. Without the freedom to openly compete, the 
clinical laboratories involved in diagnostics are still severely handcuffed, and patient 
access to testing will remain limited. 
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Biotechnology Industry Organization (BIO), Association of University Technology 
Managers (AUTM) 
 The Biotechnology Industry Organization is a trade organization that represents a 
considerable number of companies while the Association of University Technology 
Managers represents technology transfer professionals from hundreds of universities. 
These two parties jointly filed a brief supporting the reversal of the District Court’s 
decision. Their position is that the invalidation of the patents discourages innovation and 
investment. It is also argued that if the patent claims are allowed to stand, they will not 
affect patients and the advancement of science will continue unimpeded. 
 Supporting their view, there are a host of success stories where patents on isolated 
DNA molecules have promoted innovation. They range from Amgen’s patents related to 
erythropoietin to Chiron Corporation’s patents related to Hepatitis C. For Amgen, the 
patents protected their discovery while Chiron was able to attract the funding necessary 
to develop screening methods to detect the presence of Hepatitis C in the blood 
(Association for Molecular Pathology v. Myriad, 2011). The benefit of patents extends to 
research in the areas of therapeutic proteins, gene therapy, and genetic testing to name a 
few. On the other hand, the negative impact of a ruling that invalidates Myriad’s patents 
would be substantial. Patents not only mitigate some of the risk associated with investing 
in innovative products, but they also allow for companies to license the discoveries of 
academic researchers (Association for Molecular Pathology v. Myriad, 2011). This 
licensing is not only a way for academic institutions to profit but also makes academic 
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research the birthplace for many startups. This is crucial because without this transfer, 
research performed in the universities may never be translated into technology that can 
help patients (Association for Molecular Pathology v. Myriad, 2011). The experience and 
capital necessary to successfully bring a product to market resides in industry and not 
academia. In the case of emerging biotechnology firms, the importance of patents cannot 
be overstated. It often takes over ten years to translate a discovery into a marketable 
product. And with no revenue to support their operations, these startups must leverage the 
value of their patents to obtain infusions of capital necessary to survive. Should the 
patents that these firms rely so heavily on be ruled ineligible, the fallout would be 
immense. Investment in the industry would decrease and innovation would slow 
(Association for Molecular Pathology v. Myriad, 2011). There would no longer be a 
compelling reason to license patents, and academic institutions would also suffer. 
 The brief also addresses the arguments and concerns that patents on isolated DNA 
molecules will have a negative impact on the public and be a barrier to the progress of 
science (Association for Molecular Pathology v. Myriad, 2011). First, the brief suggests 
that although the power to price a product lies with the patent holder, it is the restrictive 
reimbursement programs that are limiting access. At the same time, it is misguided to 
argue after the disclosure of a discovery that the public would be better off if it were not 
patented (Association for Molecular Pathology v. Myriad, 2011). The future success of 
the industry depends on its ability to attract continued investment—specifically the early-
stage companies which hold two-thirds of the clinical pipeline (Association for Molecular 
Pathology v. Myriad, 2011). Without investors willing to shoulder the burden of 
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financing novel ideas, advances in medical science will undoubtedly slow. To address 
concerns that patenting isolated DNA molecules “stifles” basic research, the brief offers 
evidence to assuage these worries. A study conducted by the National Research Council 
in 2006 reports that academic researchers are largely unaffected by patent restrictions 
(National Research Council, 2006). As it pertains to Myriad, it appears that they have 
only asserted their patent rights against commercial competitors and left academics 
performing basic research alone. And as referenced in the Rosetta Genomics and George 
Mason University brief, a considerable amount of research has been performed and 
number of papers has been published in connection to Myriad’s BRCA1/2 patents.  
 The Federal Circuit Court’s decision, should it stand, will affect both academic 
institutions and biotechnology companies, including those focused on personalized 
medicine. Because the court ruled that patents covering the comparison of gene 
sequences were invalid, some patents that would have otherwise been granted will not be 
approved. Biotechnology companies and academic institutions may in turn shy away 
from this area of research, affecting the discovery and development of new diagnostics. 
This ruling will hurt a critical sector within personalized medicine, given much of 
personalized medicine relies on such tests. On the other hand, isolated DNA sequences 
were ruled patentable as well as a specific diagnostic method that involves screening via 
cell growth rates. Thus, companies that count isolated DNA patents among their assets 
can continue to leverage their intellectual property to pursue further advances in science. 
How this affects members of the BIO is difficult to discern because the ruling’s effect 
depends largely on what patents they hold and what kind of company they are. The effect 
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on academic institutions will also vary. One of the many factors to consider is what areas 
the institution focuses its research on. Institutions that rely heavily on licensing research 
will be more heavily impacted than those who do not. Researchers may react by shifting 
their research away from areas that do not offer patent protection. The brief, however, 
suggests that because academic research is largely unaffected by patents, the impact will 
be minimal (Association for Molecular Pathology v. Myriad, 2011). 
 
American Medical Association, American Society of Human Genetics, American 
College of Obstetricians and Gynecologists, American College of Embryology, Medical 
Society of the State of New York 
 In favor of invalidating Myriad’s patent claims, the parties that came together to 
file this brief consist predominantly of physicians and those who are involved with the 
administration of health care. As such, their perspective and opinion differ from those of 
the BIO and AUTM. It is the view of these organizations that the patents Myriad holds 
interfere negatively with medical practice and scientific innovation (Association for 
Molecular Pathology v. Myriad, 2011). This coalition also believes that there are 
sufficient incentives, aside from those related to patents, to encourage the continued 
advancement of the field of genetics. In their view, gene patents as well as patent claims 
to the comparison of genetic sequences should be invalidated. 
 Most of the organizations that filed this brief represent physicians and the views 
expressed in this brief reflect how healthcare may be affected. The advancement of health 
care has led to the increased usage of genetic sequencing for diagnosis and treatment. 
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While conceptually this bodes well for patients, the worry is that once a company 
receives a gene patent it can bar others from using that sequence to aid in diagnosing 
patients. It is suggested that this is done intentionally to protect sales of a companion 
drug—testing could exclude patients who would otherwise take the drug—or 
unintentionally due to company upheaval (Association for Molecular Pathology v. 
Myriad, 2011). Regardless of why, this interferes with the diagnosis and treatment of 
patients. Additionally, in the case of Myriad’s gene patents, the organizations involved in 
this brief believe that quality assurance is negatively impacted (Association for Molecular 
Pathology v. Myriad, 2011). Myriad’s test is the only one on the market, but new 
mutations have been discovered that are not detected by the current test (Association for 
Molecular Pathology v. Myriad, 2011). Being the only test also makes it difficult for 
patients to seek a second opinion (Association for Molecular Pathology v. Myriad, 2011). 
There are potentially serious ramifications for testing positive or negative, and patients 
are handcuffed when access and options are limited. As it relates to personalized 
medicine, whole genome sequencing becomes cost prohibitive if royalties must be paid 
for each patented gene sequence (Association for Molecular Pathology v. Myriad, 2011). 
Instead of promoting scientific and medical innovation, gene patents, it is argued, are 
actually harmful. Many laboratories that perform genetic testing either stopped 
developing new tests or stopped testing altogether (Association for Molecular Pathology 
v. Myriad, 2011). 
In addressing one of the core arguments against patent invalidation, the coalition 
argues that existing incentives are sufficient enough to encourage innovation. They 
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contend that genetic diagnostic tests have been and continue to be developed without 
patent protection. Scientists and doctors want to discover genes and develop tests based 
on them “to help mankind, to aspire to Nobel Prizes, and to achieve academic 
advancement” (Association for Molecular Pathology v. Myriad, 2011). And thus far, no 
evidence has been produced to prove that the possibility of obtaining a gene patent was 
necessary for the discovery of specific gene sequences (Association for Molecular 
Pathology v. Myriad, 2011). Perhaps more important in the eyes of the physicians it 
represents, the brief points out that patent exclusivity hurts patients. Though the 
sequencing of the genome for hepatitis C is considered a success story for the supporters 
of Myriad, the patent holder for the hepatitis C genome blocked the usage of an 
inexpensive test developed by a separate company, restricting access to testing 
(Association for Molecular Pathology v. Myriad, 2011). The brief also reveals details 
regarding the discovery and subsequent patenting of BRCA1. The Breast Cancer Linkage 
Consortium was in the process of sequencing BRCA1 with the intention of making the 
sequence publicly available (Association for Molecular Pathology v. Myriad, 2011). A 
member of the consortium, Mark Skolnick, however, founded Myriad Genetics and filed 
a patent for BRCA1 as the consortium was completing its work (Association for 
Molecular Pathology v. Myriad, 2011). Of note, while taxpayer dollars were used to fund 
the research, the patenting of BRCA1 has removed it from the public domain 
(Association for Molecular Pathology v. Myriad, 2011). 
 If the Supreme Court upholds the Federal Circuit Court’s decision, the fears and 
concerns expressed by the organizations represented in the brief will largely remain. 
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While the diagnostic claims that involved the comparison and analysis of gene sequences 
were invalidated, the patent eligibility of gene patents was upheld. In the eyes of the 
clinicians represented by the organization, this will negatively impact their ability to 
provide the best possible health care. The patent exclusivity may prove profitable for 
biotechnology companies, but the high cost of tests mean that the tests would remain 
exclusive. In addition, it is possible that the patent exclusivity removes any incentive for 
the patent-holding company to continue investing to improve the test. As pointed out in 
the brief, newly discovered mutations within the BRCA1 gene are being linked to 
increased risk, yet the currently marketed test does not detect these mutations. It is 
important to keep in mind that the addition of new correlations will likely require 
additional clinical trials and additional approval. Currently, clinicians only have one 
option and must rely solely on the test marketed by Myriad. This makes it difficult to 
seek a second opinion on test results, and knowing that the test is not comprehensive 
likely makes clinicians uneasy. In the end, while biotechnology companies that hold gene 
patents win out, the patients and providers appear to be on the losing end. Biotechnology 
companies appear to be minimally affected. Diagnostic tests that contain no 
transformative step are not patentable. Owning a gene patent is likely a strong enough 
deterrent to keep third-party firms from developing tests that rely on patented genes, 
effectively eliminating the competition. But it is worth consideration that patenting 
discoveries upstream of diagnostic correlations may end up being worse for not only 
patients but also the industry as a whole. 
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Genomic Health, Inc., Celera Corporation, XDx, Inc., Target Discovery, Inc., The 
Coalition for 21st Century Medicine, and Burrill & Company 
 The companies and organizations filing in this brief are all involved in the 
research and development of diagnostics and have an interest in sustaining the growth of 
personalized medicine. All entities believe that the court’s ruling, should it stand, 
“undermine the incentives needed to advance this new and evolving technology” 
(Association for Molecular Pathology v. Myriad, 2011). The primary incentive, as stated 
by other briefs, is money. Those in the industry highlight the immense cost associated 
with not only making discoveries but also successfully translating and bringing them to 
market (Association for Molecular Pathology v. Myriad, 2011). The companies that do 
not possess the capital themselves rely on their patent portfolios to attract the investment 
needed to test their ideas (Association for Molecular Pathology v. Myriad, 2011). The 
period of exclusivity that patent protection affords also gives companies the time 
necessary to recoup their investment. Once correlations become proven, the diagnostics 
based on them become easy to replicate (Association for Molecular Pathology v. Myriad, 
2011). While some have suggested that academia can fill the void, the current system of 
innovation relies on privately funded research (Association for Molecular Pathology v. 
Myriad, 2011). And because the skills and incentives required to commercialize research 
are very different from conducing basic research, it is difficult to assume that academia 
can take the place of privately funded ventures (Association for Molecular Pathology v. 
Myriad, 2011). 
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 Even though the Court has ruled that genes are patent eligible, the future of 
personalized medicine companies is still very much in doubt because diagnostic claims 
that contain no transformative step have been ruled ineligible. Because of this ruling, a 
fundamental shift within the personalized medicine industry may occur. Instead of 
patenting diagnostic tests and correlations, companies may instead focus on discovering 
and patenting genes. Investment in new companies is based on the strength of the patent 
portfolio, and companies that hold gene patents instead of diagnostic claims will be in a 
stronger position. Consequently, it will be increasingly difficult for startups to secure 
funding, and research may shift to larger biotechnology firms that can afford to invest in 
costly research and development. For companies about to market new tests, it is possible 
they may rethink their pricing strategy depending on how their diagnostic test is 
protected. For example, tests based on now invalidated patents may enter the market at a 
lower price and betting on higher volume. On the other hand, companies with gene 
patents can continue to monopolize the market. In the end, the pace of innovation may 
slow. Small startups tend to be more nimble and willing to test radical ideas, and with 
less of them being funded, less of these ideas will be explored. And larger companies 
may become more cautious and deliberate when researching new ideas, weary of the 
legal ramifications and potential for profit. Furthermore, academia and publically funded 
research is not currently equipped to handle the translation of basic science discoveries 
into full-fledged consumer products.  
While academic institutions may continue to research genes that have been 
patented, the patent holder will be able to dictate the impact of their discoveries on the 
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patient. Companies can choose whether or not to include new correlations or improve 
current tests. In order to maximize profits during the period of patent exclusivity, 
biotechnology firms may choose to price their tests and products to the extent that the 
market can bear. While this may lock in profits in the short term, doctors and patients 
may be resort to testing as a last resort, negatively impacting the growth of the industry. 
At the same time, companies in the personalized medicine space will need to invest more 
heavily and come up with more innovative tests because the correlations that they relied 
on in the past may now be patent ineligible. This bodes well for the industry and 
potentially patients in the long run.  
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DISCUSSION 
 
Combined Effects 
In this review, we do not cover all of the briefs filed in Mayo Collaborative 
Services et al. v. Prometheus Laboratories (2012) or Association for Molecular 
Pathology et al. v. Myriad (2011). Even so, we have discovered that among those briefs 
that were examined, there are overlapping themes and positions expressed. Most 
biotechnology companies and those who invest in them favor patent protection, but the 
opinions of those that have been sued for infringement are mixed. They must walk a fine 
line, arguing for the invalidation of the patents they have allegedly infringed, while 
shielding their own patents from persecution. These companies stand to lose if the patents 
are upheld—forcing them to cease all related activities and pay any damages awarded. 
Even if the patents are invalidated, these companies are placed in a tough position. Their 
own patents may still be affected should the Court hand down a broad decision impacting 
an entire class of patents. Consequently, companies deciding to sue for patent 
infringement must weigh the consequences. A favorable ruling is obviously beneficial, 
but when a case goes to court, the patents in question are closely scrutinized. This opens 
up the possibility of the patents being ruled invalid. At the same time, there are additional 
considerations. The patent holding company can continue performing the diagnostic test 
in question during litigation, profiting throughout litigation. On the other hand, the 
company being sued for infringement must cease all testing. In the case of an unfavorable 
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ruling, continued testing during litigation would have equated to willing infringement and 
stiffer penalties. 
When it comes to testing laboratories already in the business of diagnostics, it 
stands to reason that their stance favors the invalidation of patents covering diagnostic 
correlations with no transformative step. Two such companies, ARUP and LabCorp, file 
a brief in the case of Mayo Collaborative Services et al. v. Prometheus Laboratories, Inc. 
(2012) that reveals a more complex issue than at first glance. On the surface, invalidation 
of Prometheus’s patents would open the door for companies such as theirs to enter the 
market with competing tests based on the base diagnostic correlations. Complicating the 
issue, ARUP holds patents that cover diagnostic correlations as well. In order to 
minimize the impact of any decision by the court, the two companies are careful to argue 
for a narrow decision. Looking out for their own interests, patent invalidation of 
diagnostic correlations could further consolidate the number of companies in the business 
of diagnostics. On one hand, invalidation would effectively lower the barrier of entry for 
companies wishing to compete in the medical diagnostics space. At the same time, these 
companies must first raise the necessary capital to do so, but without patents to leverage 
as assets, it will be more difficult to attract investors. By making it more difficult for 
startups to disrupt the industry, testing laboratories such as ARUP and LabCorp can 
continue to do business as usual. Yet the increased competition amongst the companies 
that remain will threaten to shrink the margins of an already low margin business even 
further. While we did not review a brief submitted by similar companies in Association 
for Molecular Pathology et al. v. Myriad Genetics (2011), we must still consider the 
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court’s decision to uphold gene patents. For the same reasons they were against patents 
covering diagnostic correlations, testing laboratories are likely against gene patents as 
well. Gene patents are more expansive and potentially cover any diagnostic correlation 
that relies on the respective gene. For example, Myriad owns the gene patents for 
BRCA1/2 and is the only company with a commercial test, BRACAnalysis. For testing 
laboratories, gene patents could be debilitating. Patent holders can either exclude others 
from performing any tests or charge significant licensing fees. Either outcome threatens 
not only the future of diagnostics but personalized medicine as well. 
While testing laboratories would like to gain access to patent protected tests, the 
biotechnology companies invested in discovering new diagnostic correlations and 
developing them into commercial tests are fighting to protect their discoveries. Consistent 
with their interests, biotechnology companies have strongly supported the validity of 
gene patents and patents covering diagnostic correlations. Briefs filed in both cases have 
indicated that the primary motivation behind supporting patents is money. For companies 
looking for funding, and startups in particular, patents are a very important part of the 
puzzle. Patents are highly valued assets that can be used to secure funding from investors. 
The NVCA has also noted that startups that boast strong patent portfolios are more likely 
to succeed (Mayo v. Prometheus, 2012). That it be a project within a large company or a 
startup, not all ventures succeed. Research and development requires an immense amount 
of capital, and it is argued that the few successes must also cover the failures (Mayo v. 
Prometheus, 2012). Companies are in the business of making money and require a viable 
business model to sustain continued development. The temporary monopoly granted by 
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patents gives the company responsible for research and development the opportunity to 
get a return on their investment. Similar arguments are made regarding the validity of 
gene patents. 
Organizations representing health care providers and patients have also voiced 
their opinions regarding patent protection. These parties almost universally oppose patent 
protection at some level for a variety of reasons. The primary concern of patients in 
particular is access to affordable diagnostic tests. Because patent protection grants a 
period of exclusivity, a given diagnostic test is likely the only one on the market.  And 
these patent protected diagnostic tests can be expensive, something high enough to be 
cost prohibitive for patients whose insurance may not cover testing (Association for 
Molecular Pathology v. Myriad, 2011). Further complicating the issue, insurance 
providers are free to choose which diagnostic tests to cover and under what 
circumstances (Association for Molecular Pathology v. Myriad, 2011). One point has 
been made clear though: the cost of testing is very closely linked to accessibility. 
Physicians whose focus is to provide their patients with the best possible care have a 
slightly different take. Reacting to the high costs of testing, physicians may simply avoid 
tests that their patients cannot afford, causing a ripple effect. This not only hurts patients, 
but it also affects the diagnostic company and any licensees. The hope is that the removal 
of patent exclusivity will open up the field to additional competitors, which should, in 
turn, drive down costs. Increased competition in the field may also spur innovation 
amongst competitors seeking to differentiate themselves. 
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Academic institutions are in a unique position and changes in the patent eligibility 
will affect specific areas of research differently and support for the invalidation of 
diagnostic patents varies. Broadly, the Bayh-Dole Act grants control of intellectual 
property that is the result of federal funding to the respective research institution. These 
institutions stand to benefit from licensing their discoveries to startups and established 
biotechnology firms. Supporting the patent eligibility of medical diagnostics makes 
sense, but the issue is more complicated because academic research encompasses many 
disciplines and concentrations. One example is medical diagnostics. At the time of this 
writing, should the decisions made in Mayo Collaborative Services et al. v. Prometheus 
Laboratories, Inc. (2012) and Association for Molecular Pathology et al. v. Myriad 
(2011) stand, patents for diagnostic correlations that involve no transformative step are 
invalidated and hence ineligible. The researchers who supported the decision to invalidate 
patents may see this as an opportunity. No longer handcuffed, further investigation into 
correlations that were once patented can proceed. Clinical research that utilizes diagnostic 
testing may also increase. As hinted in some of the briefs covered, researchers may have 
shied away from incorporating patented diagnostic tests into their research, fearing the 
ramifications of being sued for patent infringement (Association for Molecular Pathology 
v. Myriad, 2011; Mayo v. Prometheus, 2012). They would now be free to perform the 
tests themselves. At the same time, increased competition in the field may bring down the 
cost of commercial testing, making its usage more appealing. Conversely, some academic 
institutions may favor patent eligibility for diagnostic correlations. Had the patents in the 
two cases been upheld, research would have been affected differently. It is plausible that 
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researchers will continue to apply for grants to explore new correlations, motivated by the 
possibility their discoveries may be patentable. But the multitude of existing patents 
covering diagnostic correlations will limit what is possible. 
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Personalized Medicine 
 Most of the discussion thus far has focused on diagnostics, but because 
diagnostics are consider the core of personalized medicine, many of the points made hold 
true for the personalized medicine industry as well. To summarize, the patents covering 
diagnostic correlations that do not contain a transformative step are invalid while gene 
patents are valid. The relationship between academic institutions and the personalized 
medicine industry will change. While academic institutions may continue research into 
diagnostic correlations, the discoveries made will no longer be patentable. As a result, 
when the research is published, diagnostic companies will be able to evaluate the data 
and incorporate it into new or existing tests without the need to license. On the flip side, 
costly translational research is often required to commercialize basic research findings, 
and if the fruits of this labor cannot guarantee a high enough return, the link between 
industry and academia may weaken significantly. The ensuing fallout may lead to 
academic institutions curtailing research in diagnostic correlations, putting pressure on 
diagnostic testing companies to invest in their own basic research. Incurring additional 
costs will only further shrink profit margins, further discouraging investment in the field. 
But as noted in multiple briefs from both cases, this research is costly, and there is no 
guarantee of success (Association for Molecular Pathology v. Myriad, 2011; Mayo v. 
Prometheus, 2012). Diagnostic testing companies will not be inclined to invest in 
research that cannot be patented. Without patent protection, this is no way to guarantee a 
return on investment, and companies would effectively be doing research for their 
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competitors. Upon releasing a new diagnostic, competitors will be able to develop 
follow-on tests that mimic the original. 
 Increased competition in the industry should drive down costs, but it may also 
discourage companies from investing further in diagnostics. Instead of looking for profits 
in the low margin diagnostics business, companies may pivot and focus their attention on 
other more lucrative fields. Should they choose to remain in the field of diagnostics, 
companies must find new ways to differentiate themselves from their competitors. 
Competitors may move to make their tests as comprehensive as possible. Using Myriad’s 
BRACAnalysis test as an example, new mutations in the BRCA1 gene have been 
discovered that are not currently detected. The competition could move to incorporate the 
latest data, funding additional research for known diagnostics correlations. Building 
faster and more accurate machines to perform testing is another way differentiation can 
occur, and patents can be filed protecting these advances.  Eventually, research into new 
diagnostic correlations must continue. The challenge is providing adequate incentives for 
both academia and industry to continue investing to advance the field of medical 
diagnostics. 
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Major Outcomes 
 The submission of briefs by companies and organizations that stand to be affected 
by the Court’s ruling in both cases is an indication of the power of patents. Not only must 
these entities make their own interests known, but they must also be mindful of a ruling’s 
effect on personalized medicine, specifically diagnostics. As indicated previously, the 
relationship between academia, the personalized medicine industry, patients, and health 
care providers is extremely complex. At the basic level, patients and health care providers 
are chiefly concerned with affordable access to therapy as well as access to different tests 
for the same condition. Simultaneously, it is important for the companies developing new 
tests and improving existing tests to have adequate incentives to continue doing so. 
Academic research has also been shown to play a critical role in advancing scientific 
knowledge and in part, fueling translational research. The freedom to explore ideas must 
be preserved for this to continue. 
 Though there are many parties affected by the Court’s rulings regarding patent 
eligibility, none are affected more so than the biotechnology companies invested in 
personalized medicine and diagnostics. The chief argument from companies looking to 
retain the patent eligibility of diagnostic correlations is the protection that patents 
provide. Patents are able to safeguard investments in two ways. First, patents grant a 
temporary monopoly on a given diagnostic test, preventing copycats. This is particularly 
important for diagnostic correlations because an immense amount of research must be 
done to prove the relationships, no matter how obvious they seem (Mayo v. Prometheus, 
2012). Second, patents are crucial to the business side of providing diagnostic testing. 
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Startups seeking funding must leverage their patent portfolios as assets (Mayo v. 
Prometheus, 2012). Patent protection allows companies and investors justify spending 
money to investigate new diagnostic correlations and develop new tests (Mayo v. 
Prometheus, 2012). Research is costly, and companies need the period of exclusivity 
afforded by patent protection to recoup their investment.  
At the time of this writing, the Court has ruled that gene patents are eligible and 
diagnostic correlations that involve no transformative step are ineligible (Association for 
Molecular Pathology v. Myriad, 2011). And because of this, the industry will 
undoubtedly change. The companies that own gene patents are now in a stronger position 
than those that relied on patents covering diagnostic correlations. The business model for 
companies that patented diagnostic correlations must change to accommodate the likely 
influx of competing tests. The most obvious adjustment is likely to lower the cost of 
testing. Tests might not only become cheaper but also more comprehensive. With more 
competitors, companies must find ways to differentiate themselves. One route is to 
constantly incorporate the latest research and data in an effort to be the most 
comprehensive test, while other companies may choose to develop new testing methods 
or machines in order to provide more accurate, quicker, or cheaper tests. On the surface, 
patients and providers stand to benefit. Lower costs should make testing more accessible 
while the increase in the number of options means patients and providers seeking second 
opinions have the option to do so. 
For companies to innovate and differentiate, however, they must spend money. 
Startups, in particular, are adversely affected. Often testing radical new ideas, these 
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startups will find it increasingly difficult to secure funding from venture capitalists. These 
investors may decide that investing in diagnostics companies without patent protection 
too risky. Because all signs point to it becoming more difficult to turn a profit, companies 
may shift funding, research, and development away from diagnostic correlations and their 
corresponding tests because they are no longer patent-eligible. And should a company 
choose to bring a new diagnostic test to market, there will be a shorter period of 
exclusivity as companies race to develop competing tests. This could end up affecting 
how tests are marketed and priced. The dynamics of the market may change with less 
emphasis on being the first to market; instead, companies may choose to compete by 
refining the tests of others. Academic institutions also are impacted because the patents 
they hold for diagnostic correlations are no longer valid, which in turn affect both 
existing and future licensing on these patents. It is possible that research may shift away 
from discovering new correlations and instead focus on learning more about existing 
correlations. At the same time, the gene patents they hold remain valid. 
It is yet unclear how the industry will change, but there are many possibilities to 
consider. Clinical laboratories that once spent money to develop their own tests may 
choose to outsource the development of new tests, relying on academic institutions or 
specialized research outfits instead. The number of players in the industry may increase 
or decrease. Companies with the resources, such as drug makers, may choose to enter the 
market to provide companion testing for their drugs. On the other hand, there may be 
fewer startups because of the difficulties to obtain funding. Of the many changes that will 
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occur, innovation may ultimately slow because the money needed to funding additional 
research will continue to decrease. 
With less money flowing into diagnostic correlation research, research may shift 
to different endeavors. Now ruled patent eligible, the focus may turn to gene patents 
instead of diagnostic correlations. But with a fixed number of genes in the human 
genome, the question remains: what happens when all the genes have been patented? As 
it stands, the invalidation of patents covering diagnostic correlations has prevented the 
personalized medicine industry from turning into the software industry where defensive 
patenting and litigation are rampant amongst competitors. Once there are no more genes 
to be discovered, however, it is uncertain how the biotechnology industry will respond. 
Will cross licensing become the norm? Or will strategic alliances between the established 
biotechnology companies and academic institutions dominate? 
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CONCLUSION 
 
 As an emerging field in the world of biotechnology, the personalized medicine 
landscape is ever changing. At the core of personalized medicine is diagnostics, and the 
growth of the industry is very much linked to success of this field. Personalized medicine 
would not be possible without diagnostics. Because the two are so tightly intertwined, 
events that impact one invariably affect the other. The rulings by the court in Mayo 
Collaborative Services et al. v. Prometheus Laboratories, Inc. (2012) and Association for 
Molecular Pathology et al. v. Myriad (2011) are two such examples. Combined, patents 
covering isolated gene sequences are valid while patents covering diagnostic correlations 
without a transformative step are not (Mayo v. Prometheus, 2012; Association for 
Molecular Pathology v. Myriad, 2011). In order to gain a better understanding of the 
implications of these decisions, we looked at the reaction and commentary from the 
media to put the many briefs reviewed in context. The Mayo Collaborative Services et al. 
v. Prometheus Laboratories, Inc. (2012) decision in particular has “horrified” the 
biotechnology industry and incited “minor panic” (Patenting Biology: Prometheus 
unsound | The Economist, 2012).  
It is said “innovators deserve to be rewarded for their labors,” and “patents are 
supposed to encourage innovation, not stifle it” (Genes and patents: More harm than 
good? | The Economist, 2010; Patenting Biology: Prometheus unsound | The Economist, 
2012). In an ideal setting, patents would both reward innovators for their discoveries and 
encourage innovation. This, however, is not the case. It has been widely argued that 
patent protection helps fuel the innovation that drives the continued advancement of the 
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industry. Disputing this position, some argue that patent protection for diagnostic testing 
is unnecessary because it “has low barriers to entry and is relatively cheap” (Genes and 
patents: More harm than good? | The Economist, 2010). Alternatively, patent protection 
may make companies complacent and stifle innovation, as it appears to have done to 
Myriad. Once their BRACAnalysis test was approved, Myriad shifted from innovating to 
extracting maximum profits. Instead of incorporating additional data on genetic 
mutations as it was made available into the existing test, Myriad offered a supplemental 
test at an additional cost (Pollack, 2011). To further stifle innovation, Myriad has 
aggressively asserted their patent rights and no longer shares its data with a public 
database (Allison, 2011; Pollack, 2011). The change in patentable material will have a 
trickle-down effect on academic research as well as startups. With a key incentive gone, 
it will be difficult to persuade these groups to continue innovating when they could 
instead piggy back off the discoveries of others without consequence. 
 It has become increasingly clear that on one side of the issue stand health care 
providers and patients who are primarily concerned about affordability and accessibility. 
As a result, the briefs filed by these parties argue fervently for decreased patent 
protection. What they fail to acknowledge is the resources required to successfully bring 
a product to market and create a sustainable business. On the other side stand the 
biotechnology companies that strongly support patent protection. They argue that it is this 
protection that allows for their industry to function, rewarding successful investments. 
Similarly, the industry sometimes fails to recognize that without willing patients and 
payers, their business is unsustainable. 
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 The decisions by the court in both cases have left many questions unanswered, 
and the uncertainty makes moving forward more difficult for those affected. The Mayo 
Collaborative Services et al. v. Prometheus Laboratories, Inc. (2012) decision is said to 
“[contain] little guidance as to what diagnostic steps would be ‘significant’ enough to 
convert a law of nature to a patent eligible application” (Rasheed, 2012). In the 
meantime, innovators must “rethink well-established strategies for obtaining and 
enforcing patent rights” (Haanes & Canaves, 2012). In response, claims will likely 
contain “more stringent language so that they are framed more narrowly and with greater 
specificity” in hopes of satisfying the Prometheus ruling (Fox, 2012). It is also unclear 
whether patented isolated genes would affect whole genome sequencing (Pollack, 2011). 
One thing is for certain though. The burden of existing patents has been lifted from 
clinical labs, which will be free to perform testing and capitalize on research done by 
others (Haanes & Canaves, 2012; Fox, 2011). 
 In response to the threat of increased competition, the personalized medicine 
industry and diagnostics may move towards trade secrets. The result of this move would 
be a “chilling effect on innovation” (Fox, 2012). According to Christopher Holman of the 
University of Missouri-Kansas City School of Law, “Patents give startup companies a 
chance, and the more you move to secrets, the more big companies are favored” (Fox, 
2012). Not only would this be detrimental to the industry, it would also be detrimental to 
patients and clinicians. Myriad, proprietor of the BRACAnalysis test, has already begun 
doing so (Pollack, 2011). It has stopped contributing to a public database on BRCA 
mutations maintained by the National Institutes of Health and begun building its own 
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database (Pollack, 2011). Even if the rulings are a victory for medical organizations and 
patient-advocacy group, they may end up having the opposite intended effect. Instead of 
decreased patent protection leading to increased access to information, biotechnology 
companies are responding by sharing less (Pollack, 2011). Another unintended 
consequence may be an increased dependence on proprietary information, handcuffing 
patients and shifting more power into the hands of companies like Myriad.  
While we were not able to discern with certainty the future of personalized 
medicine and the diagnostics industry, the briefs examined as well as the media reaction 
to the court’s decisions provide valuable clues as well as raise new questions. One such 
topic is taxpayer-funded research. With most research being published in expensive 
journals or otherwise inaccessible to the public, we must revisit access to publically 
funded research. In the Information Age, access to this information will become more 
prominent and important. There will always be a struggle between the for-profit 
companies in the biotechnology industry and the health care providers and their patients. 
In the future, it will continue to be important to maintain adequate incentives for the 
industry to flourish. At the same time, the availability of testing, treatment, and 
information remains crucial for clinicians and patients. The relationship between the two 
is obligate—they are dependent on one another for survival. Out of necessity, a balance 
must be struck between the two opposing sides, whether this is accomplished via 
licensing or by other means.  
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